May 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that has returned or has not responded to prior treatments. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
After market 07:59:42 pm | |||
40.49 USD | -1.82% | 40.52 | +0.07% |
May. 28 | Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License | MT |
May. 27 | Bristol Myers: will present data on schizophrenia | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.09% | 82.08B | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+12.81% | 238B | |
+6.98% | 204B | |
-6.54% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves expanded use of Bristol's cancer cell therapy